Bioventus Reports $123.9 Million in Q1 2025 Net Sales, Down 4.5% Year-Over-Year

Bioventus Inc. reported a net sales figure of $123.9 million for the first quarter of 2025, a decrease of 4.5% from $129.5 million in the same period of the previous year. The company's gross profit also declined to $83.1 million, down from $88.4 million, reflecting a gross margin of 67.1%. Operating income remained relatively stable at $4.9 million, compared to $4.9 million in the prior year, while the net loss attributable to Bioventus Inc. improved to $2.6 million from $4.9 million year-over-year. The loss per share for Class A common stock was reported at $0.04, an improvement from $0.08 in the previous year.

The company experienced notable changes in its financial performance, particularly in its cost structure. Selling, general, and administrative expenses decreased to $73.5 million from $78.8 million, while research and development expenses increased slightly to $3.0 million from $2.6 million. The reduction in SG&A expenses was attributed to ongoing cost management initiatives, which have been a focus for the company as it navigates market conditions. Additionally, Bioventus completed the divestiture of its Advanced Rehabilitation Business at the end of 2024, which is expected to impact future financial results positively by allowing the company to concentrate on its core product lines.

Operationally, Bioventus reported a total employee headcount of approximately 930 as of March 29, 2025, consistent with the previous quarter. The company continues to focus on expanding its product offerings, particularly in the Pain Treatments and Surgical Solutions segments, which generated $52.7 million and $40.8 million in sales, respectively. However, the Restorative Therapies segment saw a decline in sales to $17.0 million from $25.3 million year-over-year, indicating challenges in that area. The company is actively working on enhancing product adoption rates and increasing market share, particularly in international markets, where sales totaled $13.4 million, down from $15.2 million.

Looking ahead, Bioventus remains focused on strategic growth initiatives, including potential acquisitions and the expansion of its product pipeline. The company anticipates that the divestiture of its non-core business will allow for more efficient allocation of resources and improved financial performance in the coming quarters. Management has expressed optimism about the company's ability to navigate current market challenges and achieve its long-term objectives, although they acknowledge the uncertainties posed by external factors such as inflation and geopolitical tensions. The company plans to continue monitoring its financial health closely and adjusting its strategies as necessary to maintain a competitive edge in the medical device industry.